Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Tomsitz

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Dermatology and Therapy|March 24, 2026
A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand EczemaStefan Weißinger, Eva Oppel, Nils Kurzen, et al.
Immunotherapy|September 9, 2025
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosisLisa Arnold, Dirk Tomsitz, Raquel Buchillon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 14, 2024
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective StudyTheresa Ruf, Farnaz Rahimi, David Anz, et al.
Cancers|July 9, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous MelanomaDirk Tomsitz, Max Schlaak, Sarah Zierold, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Data in Brief|November 25, 2022
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2025
Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99]Thomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
JAMA Dermatology|October 19, 2022
Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced MelanomaZachary Cartun, Wolfgang G Kunz, Lucie Heinzerling, et al.
Immunotherapy|September 4, 2023
Tumor lysis syndrome induced by tebentafuspTheresa Ruf, Anna Leonhardt, David Anz, et al.
The British Journal of Dermatology|September 4, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II studySebastian Haferkamp, Bastian Schilling, Carola Berking, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Dermatology and Therapy|March 24, 2026
A Retrospective Real-World Comparison of Topical Delgocitinib and Localized Cream Psoralen-Ultraviolet A in Chronic Hand EczemaStefan Weißinger, Eva Oppel, Nils Kurzen, et al.
Immunotherapy|September 9, 2025
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosisLisa Arnold, Dirk Tomsitz, Raquel Buchillon, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 14, 2024
Extracorporeal Photopheresis as a Treatment Option for Immune-Related Adverse Events: Two Case Reports and a Prospective StudyTheresa Ruf, Farnaz Rahimi, David Anz, et al.
Cancers|July 9, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous MelanomaDirk Tomsitz, Max Schlaak, Sarah Zierold, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2022
Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of lifeThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
Data in Brief|November 25, 2022
Health-related quality of life (EuroQol 5D-5L) in patients with autoimmunity in the context of immunotherapy: A large dataset comprising cancer patients after cessation of checkpoint inhibitor therapy and patients with autoimmune diseasesThomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2025
Corrigendum to "Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life" [Eur J Cancer 176 (2022) 88-99]Thomas U Schulz, Sarah Zierold, Michael M Sachse, et al.
JAMA Dermatology|October 19, 2022
Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced MelanomaZachary Cartun, Wolfgang G Kunz, Lucie Heinzerling, et al.
Immunotherapy|September 4, 2023
Tumor lysis syndrome induced by tebentafuspTheresa Ruf, Anna Leonhardt, David Anz, et al.
The British Journal of Dermatology|September 4, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma - Results of a multicenter phase II studySebastian Haferkamp, Bastian Schilling, Carola Berking, et al.
Pageof 4